C4 Therapeutics Makes Auspicious Debut With Roche Tie-Up, $73m Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
On the strength of research licensed from Dana-Farber Cancer Institute, C4 will develop targeted protein degradation therapeutics against disease-causing proteins in a range of therapeutic areas that could include cancer and the central nervous system.
You may also be interested in...
Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.